These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 27197157)

  • 1. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
    Cizkova M; Cizeron-Clairac G; Vacher S; Susini A; Andrieu C; Lidereau R; Bièche I
    PLoS One; 2010 Dec; 5(12):e15647. PubMed ID: 21209903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
    Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
    Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
    Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
    Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
    Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
    Wik E; Ræder MB; Krakstad C; Trovik J; Birkeland E; Hoivik EA; Mjos S; Werner HM; Mannelqvist M; Stefansson IM; Oyan AM; Kalland KH; Akslen LA; Salvesen HB
    Clin Cancer Res; 2013 Mar; 19(5):1094-105. PubMed ID: 23319822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
    Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
    Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
    Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
    Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
    Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
    Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
    Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.